IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
PHARMACOKINETIC AND BIOEQUIVALENCE COMPARISON BETWEEN CAPSULES OF ATAZANAVIR SULFATE 300MG: AN OPEN LABEL, BALANCED, RANDOMIZED-SEQUENCE, SINGLE-DOSE, TWO-PERIOD CROSSOVER STUDY IN HEALTHY INDIAN MALE VOLUNTEERS

Author: NIDAMANURI DEVI, SRIDEVI, SUVARCHALA PATCHALA
Abstract: Bioavailability (BA) and bioequivalence (BE) studies play a major role in the drug development phase for both new drug products and their generic equivalents, and thus attract considerable attention globally. BE is a strategy to introduce generic equivalents of brand-name drugs (innovator drugs) to lower the cost of medication through proper assessment as directed by the international regulatory authorities. Concern about lowering health care costs has resulted in a tremendous increase in the use of generic drug products. Thus, Bioavailability and Bioequivalence of drug products, and drug product selection have emerged as critical issues in pharmacy and medicine during the last three decades. This present bioequivalence study was designed to determine the bioavailability and bioequivalence of atazanavir sulfate 300 mg capsules in comparison with Reyataz® 300mg capsules after single dose administration under fasting conditions in healthy adult male Indian subjects. Therefore the design of an open label, balanced, randomized, single dose, two-treatment, two-sequence, two-period crossover study with a wash-out period of at least 5 days was used.
Keyword: Bioequivalence, Pharmacokinetics, Atazanavir Sulfate, Reyataz
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free